Published online before print December 18, 2003, doi: 10.1161/01.RES.0000113781.08139.81
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on June 19, 2003
Revised on December 5, 2003
Accepted on December 11, 2003
PPAR
Activators Inhibit Vascular Endothelial Growth Factor Receptor-2 Expression by Repressing Sp1-Dependent DNA Binding and Transactivation
Markus Meissner ;
From the Department of Dermatology (M.M., M.S., K.R., R.K., J.G.), Molecular Cardiology, Department of Internal Medicine IV (C.U.), Klinikum der J.W. Goethe-Universität, Frankfurt am Main, Germany; Institut für Molekularbiologie und Tumorforschung (G.S.), Philipps-Universität, Marburg, Germany; Département d’Athérosclérose (B.S.), UR545 INSERM, Institut Pasteur de Lille, Lille, France; and the Department of Molecular Biology (J.G.), Max-Planck-Institut für Physiologische und Klinische Forschung, Bad Nauheim, Germany.
* To whom correspondence should be addressed. E-mail: Gille{at}em.uni-frankfurt.de.
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors, originally implicated in the regulation of lipid and glucose homeostasis. In addition, natural and synthetic PPAR activators may control inflammatory processes by inhibition of distinct proinflammatory genes. As signaling via the vascular endothelial growth factor receptor-2 (VEGFR2) pathway is critical for angiogenic responses during chronic inflammation, we explored whether known antiinflammatory effects of PPAR ligands are mediated in part through diminished VEGFR2 expression. In this study, PPAR
agonists are found to inhibit endothelial VEGFR2 expression, whereas predominant PPAR
ligands remained without discernible effects. Time- and concentration-dependent inhibition is demonstrated both at the level of protein and mRNA VEGFR2 expression. Inhibitory effects of PPAR agonists on transcriptional activity of the VEGFR2 promoter are conveyed by an element located between base pairs -60 and -37 that contains two adjacent consensus Sp1 transcription factor binding sites. Constitutive Sp1-containing complex formation to this sequence is decreased by PPAR treatment, indicating that VEGFR2 gene expression is inhibited by repressing Sp1 site-dependent DNA binding and trans activation. Our coimmunoprecipitation experiments revealed enhanced protein interactions between PPAR and Sp1 on PPAR activation, thus constituting a probable mechanism by which PPAR activators decrease Sp-dependent binding activity to the VEGFR2 promoter. Hence, molecular mechanisms by which PPARs modulate the rate of gene transcription may include direct interactions between specific transcription factors and PPARs that ultimately result in reduced DNA binding to their respective response elements.
Key words: endothelial growth factor receptors • peroxisome proliferator-activated receptors • inflammation • transcription factors • promoter regions
This article has been cited by other articles:
 |
|
 |
|
  R. Simo and C. Hernandez Advances in the Medical Treatment of Diabetic Retinopathy Diabetes Care, August 1, 2009; 32(8): 1556 - 1562. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Meissner, G. Reichenbach, M. Stein, I. Hrgovic, R. Kaufmann, and J. Gille Down-regulation of Vascular Endothelial Growth Factor Receptor 2 Is a Major Molecular Determinant of Proteasome Inhibitor-Mediated Antiangiogenic Action in Endothelial Cells Cancer Res., March 1, 2009; 69(5): 1976 - 1984. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Necela, W. Su, and E. A. Thompson Peroxisome Proliferator-activated Receptor {gamma} Down-regulates Follistatin in Intestinal Epithelial Cells through SP1 J. Biol. Chem., October 31, 2008; 283(44): 29784 - 29794. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Higgins, S. Liu, M. Abdelrahim, K. Vanderlaag, X. Liu, W. Porter, R. Metz, and S. Safe Vascular Endothelial Growth Factor Receptor-2 Expression Is Down-Regulated by 17{beta}-Estradiol in MCF-7 Breast Cancer Cells by Estrogen Receptor {alpha}/Sp Proteins Mol. Endocrinol., February 1, 2008; 22(2): 388 - 402. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Mochizuki and Y.-G. Kwon 15-Lipoxygenase-1 in the Vasculature: Expanding Roles in Angiogenesis Circ. Res., February 1, 2008; 102(2): 143 - 145. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Panigrahy, A. Kaipainen, S. Huang, C. E. Butterfield, C. M. Barnes, M. Fannon, A. M. Laforme, D. M. Chaponis, J. Folkman, and M. W. Kieran PPAR{alpha} agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition PNAS, January 22, 2008; 105(3): 985 - 990. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Pozzi, M. R. Ibanez, A. E. Gatica, S. Yang, S. Wei, S. Mei, J. R. Falck, and J. H. Capdevila Peroxisomal Proliferator-activated Receptor-{alpha}-dependent Inhibition of Endothelial Cell Proliferation and Tumorigenesis J. Biol. Chem., June 15, 2007; 282(24): 17685 - 17695. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Chintalgattu, G. S. Harris, S. M. Akula, and L. C. Katwa PPAR-{gamma} agonists induce the expression of VEGF and its receptors in cultured cardiac myofibroblasts Cardiovasc Res, April 1, 2007; 74(1): 140 - 150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Higgins, S. Liu, M. Abdelrahim, K. Yoon, K. Vanderlaag, W. Porter, R. P. Metz, and S. Safe Vascular Endothelial Growth Factor Receptor-2 Expression Is Induced by 17{beta}-Estradiol in ZR-75 Breast Cancer Cells by Estrogen Receptor {alpha}/Sp Proteins Endocrinology, July 1, 2006; 147(7): 3285 - 3295. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Deng, S. Shan, P.-P. Li, Z.-F. Shen, X.-P. Lu, J. Cheng, and Z.-Q. Ning Peroxisome Proliferator-Activated Receptor-{gamma} Transcriptionally Up-Regulates Hormone-Sensitive Lipase via the Involvement of Specificity Protein-1 Endocrinology, February 1, 2006; 147(2): 875 - 884. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Julan, H. Guan, J. P. van Beek, and K. Yang Peroxisome Proliferator-Activated Receptor {delta} Suppresses 11{beta}-Hydroxysteroid Dehydrogenase Type 2 Gene Expression in Human Placental Trophoblast Cells Endocrinology, March 1, 2005; 146(3): 1482 - 1490. [Abstract] [Full Text] [PDF]
|
|